surmount-1 trial tirzepatide weight loss results reduction over time in tirzepatide‐treated participants by early weight response: Post hoc analysis in SURMOUNT‐1 Tirzepatide Treatment Leads to Weight

This observation likely reflects that MIA-induced OA primarily targets cartilage, whereas changes of the subchondral bone occur secondarily and can be influenced by factors such as mechanical loading, individual variability, and baseline bone status 52

Treatment discontinuation also negatively impacted blood sugar control in patients with prediabetes

The good news is that it remains temporary

Your thyroid and endocrine provider should communicate during tirzepatide treatment

However, future long-term studies are needed to add to the growing evidence

According to the Medicines and Healthcare products Regulatory Agency (MHRA) approved Summary of Product Characteristics (SmPC), dizziness is listed as a common adverse reaction (affecting up to 1 in 10 people)